OpenLB
Open Library of Bioscience
Advanced Search
Microbiology insights
2016;9 9-19.

Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Neelam Taneja, Harsimran Kaur
Author Information
  1. Neelam Taneja: Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  2. Harsimran Kaur: Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
PMID: 27013887 DOI: 10.4137/MBI.S29459

Abstract

Currently, drug resistance, especially against cephalosporins and carbapenems, among gram-negative bacteria is an important challenge, which is further enhanced by the limited availability of drugs against these bugs. There are certain antibiotics (colistin, fosfomycin, temocillin, and rifampicin) that have been revived from the past to tackle the menace of superbugs, including members of Enterobacteriaceae, Acinetobacter species, and Pseudomonas species. Very few newer antibiotics have been added to the pool of existing drugs. There are still many antibiotics that are passing through various phases of clinical trials. The initiative of Infectious Disease Society of America to develop 10 novel antibiotics against gram-negative bacilli by 2020 is a step to fill the gap of limited availability of drugs. This review aims to provide insights into the current and newer drugs in pipeline for the treatment of gram-negative bacteria and also discusses the major challenging issues for their management.

Keywords

carbapenem resistance challenges in management drug resistance gram-negative bacteria novel antibiotics

References

  1. Expert Rev Anti Infect Ther. 2014 Nov;12(11):1311-24 [PMID: 25139127]
  2. Drugs. 2013 Feb;73(2):159-77 [PMID: 23371303]
  3. J Antimicrob Chemother. 2014 Sep;69(9):2326-36 [PMID: 24872344]
  4. Expert Rev Anti Infect Ther. 2013 Dec;11(12):1333-53 [PMID: 24191943]
  5. Clin Microbiol Infect. 2012 Jan;18(1):4-7 [PMID: 21914036]
  6. J Infect. 2009 Feb;58(2):138-44 [PMID: 19058855]
  7. Iran J Basic Med Sci. 2012 Mar;15(2):693-701 [PMID: 23494063]
  8. Antimicrob Agents Chemother. 2014;58(2):1127-35 [PMID: 24295985]
  9. J Med Liban. 2012 Jul-Sep;60(3):142-7 [PMID: 23198454]
  10. Antimicrob Agents Chemother. 2010 Jan;54(1):526-9 [PMID: 19901089]
  11. Antimicrob Agents Chemother. 2013 Aug;57(8):3990-3 [PMID: 23752510]
  12. Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94 [PMID: 21555763]
  13. Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):127-42 [PMID: 19915879]
  14. Antimicrob Agents Chemother. 2013 May;57(5):2388-90 [PMID: 23439635]
  15. J Clin Med Res. 2013 Apr;5(2):97-100 [PMID: 23519391]
  16. Curr Infect Dis Rep. 2011 Oct;13(5):416-25 [PMID: 21800232]
  17. Int J Infect Dis. 2014 Jan;18:62-7 [PMID: 24246741]
  18. J Antimicrob Chemother. 2014 Feb;69(2):564-7 [PMID: 24080500]
  19. Antimicrob Agents Chemother. 2011 Dec;55(12):5685-95 [PMID: 21911563]
  20. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58 [PMID: 23979750]
  21. Mol Syst Biol. 2011 Aug 16;7:521 [PMID: 21847113]
  22. Antibiotics (Basel). 2013 Dec 06;2(4):500-34 [PMID: 27029317]
  23. Antimicrob Agents Chemother. 2005 Nov;49(11):4448-54 [PMID: 16251282]
  24. Clin Microbiol Infect. 2014 Feb;20(2):O117-23 [PMID: 23992130]
  25. J Antimicrob Chemother. 2011 Nov;66(11):2628-31 [PMID: 21810837]
  26. J Antimicrob Chemother. 1996 Jun;37(6):1155-64 [PMID: 8836818]
  27. J Infect Dev Ctries. 2014 Feb 13;8(2):129-36 [PMID: 24518621]
  28. J Infect Dis. 2013 Oct 1;208(7):1142-51 [PMID: 23812239]
  29. Clin Infect Dis. 2011 Nov;53(9):879-84 [PMID: 21900484]
  30. Int J Antimicrob Agents. 2013 Jun;41(6):582-5 [PMID: 23611306]
  31. Antimicrob Agents Chemother. 2012 May;56(5):2559-64 [PMID: 22354310]
  32. Expert Rev Clin Pharmacol. 2015;8(6):691-707 [PMID: 26420166]
  33. Antimicrob Agents Chemother. 2010 May;54(5):1955-64 [PMID: 20176911]
  34. J Chemother. 2007 Aug;19(4):388-91 [PMID: 17855182]
  35. J Clin Microbiol. 2012 Nov;50(11):3747-50 [PMID: 22933593]
  36. Drugs. 2014 Jan;74(1):31-51 [PMID: 24352909]
  37. Curr Opin Pharmacol. 2014 Oct;18:91-7 [PMID: 25277839]
  38. Ups J Med Sci. 2014 May;119(2):149-53 [PMID: 24666223]
  39. Antimicrob Agents Chemother. 2008 Feb;52(2):570-3 [PMID: 18070960]
  40. Thorax. 2010 Jun;65(6):553 [PMID: 20522858]
  41. Expert Rev Anti Infect Ther. 2012 Apr;10(4):459-73 [PMID: 22512755]
  42. Antimicrob Agents Chemother. 2012 Mar;56(3):1606-8 [PMID: 22214778]
  43. Clin Infect Dis. 2008 Feb 15;46(4):567-70 [PMID: 18199038]
  44. Antimicrob Agents Chemother. 2010 Jun;54(6):2732-4 [PMID: 20368401]
  45. Antimicrob Agents Chemother. 2013 Apr;57(4):1978-81 [PMID: 23380726]
  46. Pharmacotherapy. 2009 Sep;29(9):1054-60 [PMID: 19698010]
  47. Clin Microbiol Infect. 2011 Nov;17(11):E9-E11 [PMID: 21939468]
  48. Chem Biol. 2003 Jun;10(6):563-71 [PMID: 12837389]
  49. Int J Med Sci. 2008;5(6):371-6 [PMID: 19043609]
  50. J Antimicrob Chemother. 2013 Oct;68(10):2286-90 [PMID: 23696619]
  51. Drug Des Devel Ther. 2015 Jun 04;9:2919-25 [PMID: 26082619]
  52. Clin Microbiol Infect. 2008 Sep;14(9):816-27 [PMID: 18844682]
  53. Antimicrob Agents Chemother. 2012 Oct;56(10):5103-12 [PMID: 22802247]
  54. Clin Microbiol Infect. 2012 Mar;18(3):268-81 [PMID: 21793988]
  55. Int J Antimicrob Agents. 2009 Aug;34(2):111-20 [PMID: 19403273]
  56. Drugs. 2013 Nov;73(17):1951-66 [PMID: 24202878]
  57. Drugs. 2001;61(6):713-21 [PMID: 11398904]
  58. Drugs. 2009 Oct 1;69(14):1879-901 [PMID: 19747006]
  59. Antimicrob Agents Chemother. 2011 Feb;55(2):649-58 [PMID: 21135179]
  60. Antimicrob Agents Chemother. 2011 Sep;55(9):4394-7 [PMID: 21709094]
  61. Infect Drug Resist. 2013 Nov 29;6:215-23 [PMID: 24348053]
  62. Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1459-70 [PMID: 21958044]
  63. Antimicrob Agents Chemother. 2013 Nov;57(11):5743-6 [PMID: 23979745]
  64. J Antimicrob Chemother. 2011 Apr;66(4):946-7 [PMID: 21393203]
  65. J Chemother. 2009 Feb;21(1):58-62 [PMID: 19297274]
  66. Antimicrob Agents Chemother. 2013 Apr;57(4):1982-8 [PMID: 23380730]
  67. Clin Infect Dis. 2015 May 15;60(10):1462-71 [PMID: 25670823]
  68. Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60 [PMID: 21859938]
  69. Antimicrob Agents Chemother. 2014;58(3):1279-83 [PMID: 24041885]
  70. Clin Infect Dis. 2010 Apr 15;50(8):1081-3 [PMID: 20214473]
  71. Int J Antimicrob Agents. 2010 Jan;35(1):39-44 [PMID: 19815392]
  72. Clin Microbiol Infect. 2010 Aug;16(8):1230-6 [PMID: 19732088]
  73. Int J Antimicrob Agents. 2010 Mar;35(3):240-3 [PMID: 20034765]
  74. J Antimicrob Chemother. 2010 Dec;65(12):2645-9 [PMID: 20876621]
  75. Clin Infect Dis. 2010 Dec 1;51(11):1238-44 [PMID: 20973727]
  76. Int J Antimicrob Agents. 2014 Jun;43(6):527-32 [PMID: 24796217]
  77. Clin Microbiol Rev. 2012 Oct;25(4):682-707 [PMID: 23034326]
  78. Infect Dis (Lond). 2017 Nov - Dec;49(11-12):867-870 [PMID: 28695756]
  79. Antimicrob Agents Chemother. 2009 May;53(5):2133-5 [PMID: 19258266]
  80. PLoS One. 2013 Dec 26;8(12):e84409 [PMID: 24386374]
  81. Biochem Pharmacol. 2006 Mar 30;71(7):919-29 [PMID: 16289393]
  82. Int J Antimicrob Agents. 2009 Dec;34(6):506-15 [PMID: 19828298]
  83. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1537-43 [PMID: 23294697]
  84. Clin Infect Dis. 2009 Jan 1;48(1):1-12 [PMID: 19035777]
  85. J Biol Chem. 2013 Sep 27;288(39):27960-71 [PMID: 23913691]
  86. Ann Intensive Care. 2011 May 25;1(1):14 [PMID: 21906345]
  87. Diagn Microbiol Infect Dis. 2012 Nov;74(3):213-23 [PMID: 22959816]
  88. Pharmacotherapy. 2015 Aug;35(8):755-70 [PMID: 26289307]
  89. Diagn Microbiol Infect Dis. 2013 Apr;75(4):331-6 [PMID: 23357291]
  90. J Med Microbiol. 2013 Aug;62(Pt 8):1184-1189 [PMID: 23699064]
  91. Biochem Soc Trans. 2012 Dec 1;40(6):1549-52 [PMID: 23176515]
  92. Int J Antimicrob Agents. 2013 Jun;41(6):499-508 [PMID: 23507414]
  93. J Appl Microbiol. 2011 Mar;110(3):778-85 [PMID: 21241420]
  94. Clin Pharmacokinet. 2009;48(9):575-84 [PMID: 19725592]
  95. Eur J Clin Microbiol Infect Dis. 2007 Nov;26(11):777-83 [PMID: 17668253]
  96. Anesthesiology. 2012 Dec;117(6):1335-47 [PMID: 23132092]
  97. Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42 [PMID: 20065058]
  98. Eur Respir J. 2012 Oct;40(4):1014-23 [PMID: 22743672]
  99. J Antimicrob Chemother. 2005 Aug;56(2):413-5 [PMID: 15980093]
  100. J Antimicrob Chemother. 2007 Apr;59(4):786-90 [PMID: 17307769]
  101. Antimicrob Agents Chemother. 2011 Feb;55(2):593-9 [PMID: 21115786]
  102. Lancet Infect Dis. 2010 Jan;10(1):43-50 [PMID: 20129148]
  103. Int J Antimicrob Agents. 2012 Apr;39(4):283-94 [PMID: 22386741]
  104. PLoS One. 2011;6(12):e28177 [PMID: 22162759]
  105. Int J Antimicrob Agents. 2014 Apr;43(4):370-4 [PMID: 24560919]
  106. Crit Care. 2005 Feb;9(1):R53-9 [PMID: 15693967]
  107. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302 [PMID: 20308379]
  108. Antimicrob Agents Chemother. 2009 May;53(5):1868-73 [PMID: 19223638]
  109. J Antimicrob Chemother. 2008 Feb;61(2):382-8 [PMID: 18070831]
Journal Article Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0antibioticsgram-negativedrugsresistancebacteriadruglimitedavailabilityspeciesnewernovelmanagementCurrentlyespeciallycephalosporinscarbapenemsamongimportantchallengeenhancedbugscertaincolistinfosfomycintemocillinrifampicinrevivedpasttacklemenacesuperbugsincludingmembersEnterobacteriaceaeAcinetobacterPseudomonasaddedpoolexistingstillmanypassingvariousphasesclinicaltrialsinitiativeInfectiousDiseaseSocietyAmericadevelop10bacilli2020stepfillgapreviewaimsprovideinsightscurrentpipelinetreatmentalsodiscussesmajorchallengingissuesInsightsNewerAntimicrobialAgentsGram-negativeBacteriacarbapenemchallenges

Similar Articles

Cited By